SCHEMBL15416459

SCHEMBL15416459

Cc1c(C(=O)O)n[c]nc1N1CCNCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.35
LMNA P02545 1/20 0.33
CYP2C9 P11712 1/20 0.33
ATP6V1B2 P21281 1/20 0.33
TBXA2R P21731 1/20 0.33
EDNRA P25101 1/20 0.33
TARBP2 Q15633 1/20 0.33
ALDH1A1 P00352 2/20 0.32
ACVR1 Q04771 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 3/20 0.32
USP2 O75604 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP2D6 P10635 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
HTR2C P28335 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
ADRB1 P08588 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15416210 0.88 ACVR1 (0.40) PDE10AACVR1HRH4
SCHEMBL15415371 0.86 ALDH1A1 (0.36) ALDH1A1
SCHEMBL15414949 0.84 CHRM3 (0.36) CYP2C9ALDH1A1CYP2D6CYP3A4
SCHEMBL15414963 0.82 ALDH1A1 (0.42) ALDH1A1POLBHSD17B10
SCHEMBL15414822 0.81 LMNA (0.35) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL874422 0.73 HRH1 (0.41) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2339894 0.72 HRH1 (0.39) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL15415956 0.71 KDM4E (0.42) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL15415214 0.69 OPRK1 (0.38) ALDH1A1POLB
SCHEMBL23536762 0.68 HTR2C (0.44) ALDH1A1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9475820-B2 Substituted imidazo[1,2-a]pyrazines as TNF activity modulators UCB BIOPHARMA SPRL (BE) 2016-10-25 US disclosed
US-20150191482-A1 Imidazopyrazine Derivatives as Modulators of TNF Activity UCB BIOPHARMA SPRL (BE) 2015-07-09 US disclosed
EP-2872511-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
WO-2014009296-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191482-A1 Imidazopyrazine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, NFKBIA PDE10A 1893/4885LMNA 3961/4885CYP2C9 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.